JP2018525371A - アリール置換された二環式ヘテロアリール化合物 - Google Patents

アリール置換された二環式ヘテロアリール化合物 Download PDF

Info

Publication number
JP2018525371A
JP2018525371A JP2018504757A JP2018504757A JP2018525371A JP 2018525371 A JP2018525371 A JP 2018525371A JP 2018504757 A JP2018504757 A JP 2018504757A JP 2018504757 A JP2018504757 A JP 2018504757A JP 2018525371 A JP2018525371 A JP 2018525371A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
alkoxy
alkylene
fluoroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2018504757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525371A5 (https=
Inventor
シャオジュン・ジャン
シャオファン・ジェン
ルイーズ・エス・チュパック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2018525371A publication Critical patent/JP2018525371A/ja
Publication of JP2018525371A5 publication Critical patent/JP2018525371A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2018504757A 2015-07-30 2016-07-28 アリール置換された二環式ヘテロアリール化合物 Ceased JP2018525371A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562198706P 2015-07-30 2015-07-30
US62/198,706 2015-07-30
PCT/US2016/044388 WO2017019828A1 (en) 2015-07-30 2016-07-28 Aryl substituted bicyclic heteroaryl compounds

Publications (2)

Publication Number Publication Date
JP2018525371A true JP2018525371A (ja) 2018-09-06
JP2018525371A5 JP2018525371A5 (https=) 2019-08-15

Family

ID=56609996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018504757A Ceased JP2018525371A (ja) 2015-07-30 2016-07-28 アリール置換された二環式ヘテロアリール化合物

Country Status (6)

Country Link
US (1) US10517870B2 (https=)
EP (1) EP3328839A1 (https=)
JP (1) JP2018525371A (https=)
KR (1) KR20180030913A (https=)
CN (1) CN108137514A (https=)
WO (1) WO2017019828A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190292176A1 (en) 2016-07-14 2019-09-26 Bistol-Myers Squibb Company Bicyclic heteroaryl substituted compounds
KR102494647B1 (ko) 2016-07-14 2023-01-31 브리스톨-마이어스 스큅 컴퍼니 비시클릭 헤테로아릴 치환된 화합물
CN109689664B (zh) 2016-07-14 2022-04-15 百时美施贵宝公司 作为par4抑制剂的三环杂芳基取代的喹啉和氮杂喹啉化合物
US10815224B2 (en) 2016-07-14 2020-10-27 Bristol-Myers Squibb Company Monocyclic heteroaryl substituted compounds
WO2019113312A1 (en) * 2017-12-08 2019-06-13 Innocrin Pharmaceuticals, Inc. Anticancer compound process
CN111440161B (zh) * 2020-05-15 2023-04-14 中国药科大学 一种具有par4拮抗活性的二环杂芳基类化合物及其应用
CN111440146B (zh) * 2020-05-15 2022-10-21 中国药科大学 一种具有par4拮抗活性的苯并三嗪类化合物及其应用
CN116041341B (zh) * 2022-11-24 2025-02-28 中国药科大学 一种喹唑啉类par4拮抗剂及其医药应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06503093A (ja) * 1990-11-26 1994-04-07 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 置換された縮合複素環式除草剤
JP2009023986A (ja) * 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
WO2010052448A2 (en) * 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
JP2011520941A (ja) * 2008-05-23 2011-07-21 ノバルティス アーゲー キノキサリン−およびキノリン−カルボキシアミド誘導体
WO2011156610A2 (en) * 2010-06-09 2011-12-15 Gilead Sciences, Inc. Inhibitors of hepatitis c virus
JP2012522741A (ja) * 2009-04-02 2012-09-27 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング キノキサリン誘導体並びに良性の及び悪性の腫瘍疾患の治療のためのその使用
EP2514749A1 (en) * 2009-12-15 2012-10-24 Shionogi & Co., Ltd. Oxadiazole derivative having endothelial lipase inhibitory activity
JP2013503824A (ja) * 2009-09-04 2013-02-04 バイエル・ファルマ・アクチェンゲゼルシャフト チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1164459A (en) 1980-11-11 1984-03-27 Yung-Hsiung Yang Process for preparing (imidazo¬1,2-a|pyridine- 2-yl)-carbostyril or -3,4-dihydrocarbostyryl derivatives
TW279162B (https=) 1991-09-26 1996-06-21 Mitsubishi Chem Corp
DE69723863T2 (de) 1996-11-06 2004-04-15 Darwin Discovery Ltd., Slough Chinoline und deren therapeutische verwendung
CA2319554C (en) * 1998-03-31 2005-06-28 Warner-Lambert Company Quinoxalinones as serine protease inhibitors such as factor xa and thrombin
CA2534649A1 (en) * 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
TWI378934B (en) * 2004-04-02 2012-12-11 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
ZA200705872B (en) * 2005-01-14 2008-09-25 Genelabs Tecnologies Inc Indole derivatives for treating viral infections
US9370508B2 (en) * 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
PE20090288A1 (es) * 2007-05-10 2009-04-03 Smithkline Beecham Corp Derivados de quinoxalina como inhibidores de la pi3 quinasa
PE20090717A1 (es) * 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
WO2009021083A1 (en) * 2007-08-09 2009-02-12 Smithkline Beecham Corporation Quinoxaline derivatives as pi3 kinase inhibitors
MY162760A (en) * 2007-09-17 2017-07-14 Abbvie Bahamas Ltd Anti-infective agents and uses thereof
SI2373172T1 (sl) * 2008-12-03 2013-12-31 Presidio Pharmaceuticals, Inc. Inhibitorji HCV NS5A
TWI428332B (zh) * 2009-06-09 2014-03-01 Hoffmann La Roche 雜環抗病毒化合物
US20110274648A1 (en) * 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
ES2677946T3 (es) 2009-11-18 2018-08-07 National Research Council Of Canada Monómeros, oligómeros y polímeros fluorados para su uso en dispositivos electrónicos orgánicos
WO2012071414A2 (en) 2010-11-22 2012-05-31 Board Of Regents Of The University Of Nebraska Quinoxaline compounds and uses thereof
HRP20190128T1 (hr) * 2011-05-04 2019-03-08 Rhizen Pharmaceuticals S.A. Novi spojevi kao modulatori protein kinaza
CN102532932B (zh) 2012-01-12 2014-01-08 复旦大学 一类含有吡嗪环的有机染料及其制备方法和应用
JP6280546B2 (ja) * 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
HK1211033A1 (en) 2012-12-20 2016-05-13 Bayer Pharma Aktiengesellschaft Bet-protein-inhibiting dihydroquinoxalinones
EP3010918B1 (en) * 2013-06-21 2018-08-15 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06503093A (ja) * 1990-11-26 1994-04-07 イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー 置換された縮合複素環式除草剤
JP2009023986A (ja) * 2006-11-08 2009-02-05 Pharma Ip 抗癌剤としてのビアリール誘導体
JP2011520941A (ja) * 2008-05-23 2011-07-21 ノバルティス アーゲー キノキサリン−およびキノリン−カルボキシアミド誘導体
WO2010052448A2 (en) * 2008-11-05 2010-05-14 Ucb Pharma S.A. Fused pyrazine derivatives as kinase inhibitors
JP2012522741A (ja) * 2009-04-02 2012-09-27 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング キノキサリン誘導体並びに良性の及び悪性の腫瘍疾患の治療のためのその使用
JP2013503824A (ja) * 2009-09-04 2013-02-04 バイエル・ファルマ・アクチェンゲゼルシャフト チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2514749A1 (en) * 2009-12-15 2012-10-24 Shionogi & Co., Ltd. Oxadiazole derivative having endothelial lipase inhibitory activity
WO2011156610A2 (en) * 2010-06-09 2011-12-15 Gilead Sciences, Inc. Inhibitors of hepatitis c virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 2, JPN6020020048, 2009, pages 397 - 400, ISSN: 0004428937 *
TETRAHEDRON LETTERS, vol. 30, no. 8, JPN6020020049, 1989, pages 935 - 936, ISSN: 0004428938 *

Also Published As

Publication number Publication date
US10517870B2 (en) 2019-12-31
CN108137514A (zh) 2018-06-08
WO2017019828A1 (en) 2017-02-02
US20180214445A1 (en) 2018-08-02
EP3328839A1 (en) 2018-06-06
KR20180030913A (ko) 2018-03-26

Similar Documents

Publication Publication Date Title
JP2018525371A (ja) アリール置換された二環式ヘテロアリール化合物
CN105636953B (zh) 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
JP7102388B2 (ja) 単環式ヘテロアリール置換化合物
CN109689649B (zh) 经二环杂芳基取代的化合物
WO2020249079A1 (zh) 一种shp2磷酸酶变构抑制剂
TWI654172B (zh) 環烷基甲酸類衍生物、其製備方法及其在醫藥上的應用
TW202321263A (zh) 磺醯胺衍生物、其製備方法及其在醫藥上的應用
WO2020063792A1 (zh) 吲哚类大环衍生物、其制备方法及其在医药上的应用
JP2019532988A (ja) Ｂ型肝炎ウイルス感染の治療又は予防のための新規テトラヒドロイソキノリン類とテトラヒドロナフチリジン類
TW202035412A (zh) 雜芳基二氫嘧啶衍生物和治療ｂ型肝炎感染之方法
CN116600808B (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
JP2024533551A (ja) ナフチルアミン構造を有する低分子化合物とその使用
CN109311865A (zh) 抗乙肝病毒的吡唑-噁唑烷酮类化合物
EP4118080B1 (en) Bcl-2 family proteins modulating compounds for cancer treatment
CN104725295A (zh) 芳杂环类衍生物及其在药物上的应用
JP2006522023A (ja) 虚血損傷治療のための４−［（２，４−ジクロロ−５−メトキシフェニル）アミノ］−６−アルコキシ−３−キノリンカルボニトリル
CN116969918A (zh) 氟取代的吡啶酮类衍生物及其药物组合物、制备方法和用途
WO2025021158A1 (zh) 螺环烯基类或氮杂烯基类化合物及其药物组合物、制备方法和用途
CN110818611A (zh) 一类吲哚酮类化合物、其制备方法、药物组合物和用途
CN115557898B (zh) 一种咪唑类化合物、其中间体及应用
TWI905781B (zh) 脯胺醯羥化酶抑制劑及其用途
CN118772113A (zh) 作为DNA聚合酶Theta抑制剂的含氮杂环化合物
AU2022292903A1 (en) 3-substituted 1h-pyrrolo[2,3-b]pyridine as grk5 modulators
HK40118212A (zh) Nlrp3炎症小体抑制剂及其应用
WO2020111252A1 (ja) Ｄｏｃｋ１阻害化合物およびその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190704

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190704

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210203

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210407

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20210727